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Presented is the ﬁrst case of acute immune reconstitution in-
ﬂammatory syndrome (IRIS)-associated cryptococcal meningo-
encephalitis in a patient on natalizumab for multiple sclerosis.
The patient developed acute cerebral edema after initiation of
amphotericin B. We propose several mechanisms that explain
the acuity of IRIS in this speciﬁc patient population and suggest
possible therapies.
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Cryptococcus neoformans is an encapsulated yeast ubiquitous in
nature that typically causes disease in patients with severe immu-
nosuppressive conditions such as human immunodeﬁciency virus
(HIV)/acquired immune deﬁciency syndrome (AIDS) or organ
transplantation. Meningoencephalitis is the most common form
of disseminated cryptococcosis and may cause severe inﬂamma-
tion in the central nervous system (CNS). Immune reconstitution
inﬂammatory syndrome (IRIS) is a well described complication of
effective treatment for CNS cryptococcosis, leading to an increased
risk for morbidity and mortality secondary to increased intracrani-
al pressure (ICP) [1,2].Corticosteroids are often used as an adjunct
to antifungal therapy for treatment of IRIS [1].
Natalizumab is a monoclonal antibody against the cell adhe-
sion molecule α4-integrin and prevents transmigration of leuko-
cytes across the blood brain barrier, reducing the CNS leukocyte
count and inﬂammation caused by autoimmune diseases, and it
has US Food and Drug Administration approval to treat relaps-
ing remitting multiple sclerosis (RRMS). Natalizumab has been
associated with progressive multifocal leukoencephalopathy
and gastrointestinal cryptosporidiosis [3].
CASE REPORT
A 46-year-old man with RRMS who had been receiving natali-
zumab for 2 years presented to the hospital with nausea, vom-
iting, headache, and poor appetite, which developed 2 months
before this presentation. He was given a diagnosis of a viral ill-
ness by his physician. He did not improve, and over the next
several weeks he developed progressive loss of vision in the
right eye, horizontal diplopia, and tinnitus. He presented to
an outside hospital the week before admission where magnetic
resonance imaging (MRI) demonstrated bilateral thalamic le-
sions. He was treated with intravenous Solu-Medrol for pre-
sumed multiple sclerosis (MS) exacerbation. He was given a
prednisone taper on discharge; however, he did not improve
and was admitted to our institution. At that time, he reported
no respiratory symptoms, and he had no other signiﬁcant past
medical, surgical, or family history. His last dose of natalizumab
was 2 months before this admission.
At presentation he was alert, oriented, and afebrile with nor-
mal vital signs. His physical and neurologic exam was notable
for decreased vision in the right eye, 6th nerve palsy on the
right, and nuchal rigidity.
An MRI was performed and demonstrated abnormal T2/
FLAIR deep gray matter hyperintense lesions most pronounced
in the basal ganglia bilaterally. Lumbar puncture (LP) was per-
formed and showed opening pressure of 32 cm water, cerebro-
spinal ﬂuid (CSF) glucose 50 mg/dL, protein 27 mg/dL, and
white blood cell count (WBC) 2041/cmm (88% lymphocytes,
12% macrophages). Cerebrospinal ﬂuid cryptococcal antigen
was positive at a titer of 1:5120; CSF culture was positive for
C neoformans. Human immunodeﬁciency virus serum assay
and JC virus CSF reverse transcription-polymerase chain reac-
tion were negative.
Amphotericin B lipid complex and ﬂucytosine were initiated
on the day of admission, and systemic corticosteroids were ta-
pered. Repeat LP performed on hospital day 3 demonstrated an
opening pressure of 14 cm water, glucose of 23 mg/dL, protein of
41 mg/dL,WBC of 436/cmm (68% lymphocytes, 6%macrophag-
es). He had persistent headaches but otherwise was stable until
hospital day 5 when he became febrile and developed seizure-
like activity. A repeat computed tomography (CT) scan of the
head was unchanged. On hospital day 6, he developed more seiz-
ure-like activity together with rapid decline in mental status. He
was transferred to the intensive care unit where he was intubated
for airway protection and had a Glasgow Coma Scale of 3. Chest
radiograph demonstrated diffuse right lower lobe inﬁltrates con-
sistent with aspiration pneumonia, and his left lung was clear. He
became hypertensive (blood pressure 200/120) and became
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progressively unresponsive. A repeat CT head scan at that point
showed severe diffuse brain swelling. The patient did not recover
brainstem reﬂexes and was declared brain dead on hospital day 7.
An autopsy was performed, which demonstrated bilateral
fungal pneumonia. Gross examination of the brain revealed
mucinous vacuolations within the basal ganglia. Microscopic
examination of the brain revealed edema, reactive astrocytosis,
and numerous budding yeasts in the leptomeninges and peri-
vascular spaces of the cerebral cortex, hippocampus, basal gan-
glia, brainstem, cerebellum, pituitary gland, and spinal cord.
DISCUSSION
This is the ﬁrst reported case of IRIS-associated with natalizumab
and cryptococcal meningitis and the second case of cryptococ-
cal meningitis associated with natalizumab [4]. Cryptococcal-
associated IRIS is classically seen among HIV/AIDS patients
after the initiation of antiretroviral therapy [2], but it is also oc-
casionally seen in immunocompetent patients with cryptococ-
cal meningitis [5].Patients taking natalizumab are at high risk of
IRIS upon discontinuation of the medicine independent of any
opportunistic infections [6].Treatment for IRIS after cryptococ-
cal meningitis is not well deﬁned, but induction therapy with
glucocorticosteroids with a prolonged taper is commonly prac-
ticed [1].
Cryptococcus has unique afﬁnity for the CNS and gains access
by manipulating the host response at the cellular and molecular
level via multiple independent mechanisms. Transcytosis seems
to be the predominant process leading to CNS penetration, as
demonstrated by murine studies using Cryptococcus-like poly-
styrene microspheres [7]. Trojan horse entry, which involves
passive transfer of Cryptococcus into the CNS within host mac-
rophages, has also been demonstrated. This method of CNS
Figure 1. (A) Axial noncontract 3D FLAIR-SENSE magnetic resonance image, hospital day 1, showing areas of hyperintensity in the basal ganglia bilaterally representing
ischemic infarcts due to cryptococcal vasculopathy. (B) Axial noncontrast computed tomography (CT) head, hospital day 9, after the initial seizure-like event. (C) Axial non-
contrast CT head, hospital day 10, after the acute decline in neurologic status showing the interval development of diffuse cerebral edema. (D) Representative hematoxylin and
eosin stain of cerebral white matter from the frontal lobe showing Cryptococcus (black arrows) with classic “soap bubble” appearance and surrounding tissue destruction.
Microglia (white arrowhead) and reactive astrocytes (white arrows) are also present. The left side shows intact neuropil (pink, strands in the background) as well as more
microglia and scattered oligodendrocytes (black arrowhead).
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entry is supported by studies demonstrating that mice given
Cryptococcus-infected macrophages elicited higher rates of
cryptococcal meningitis than those given injections of free-
living organisms [8]. More importantly, virulence factors also
likely play an important role in allowing cryptococcal penetra-
tion with studies suggesting a role for cryptococcal urease,
plasmin, and inositol [9, 12].
Natalizumab is indicated for the treatment of relapsing/
remitting MS. Although the mechanisms responsible for its ef-
ﬁcacy have yet to be completely elucidated, natalizumab causes
a profound decrease in CNS CD4/CD8 cells to levels compara-
ble to patients with advanced HIV/AIDS [9]. In addition, it may
decrease the amount of antigen-presenting cells in the CSF,
causing the immunosuppressive effect to persist months after
discontinuation of therapy [10]. Such profound localized CNS
immunosuppression has been demonstrated to increase the
risk for CNS infections typically associated with HIV/AIDS,
such as progressive multifocal leukoencephalopathy [3]. More
importantly, natalizumab-mediated immunosuppression is
unique in that it is compartmentalized to the CNS only, with
patients exhibiting normal peripheral CD4 T-cell populations
[9]. In stark contrast, patients with HIV/AIDS exhibit profound
loss of both peripheral and CNS CD4 populations.
This patient developed cryptococcal meningitis likely as a re-
sult of immunomodulation with natalizumab and corticosteroids
for MS. The worsening headache, vision loss, and MRI with bi-
lateral thalamic lesions represented the initial presentation of
cryptococcal disease because MS lesions are typically found in
juxtacortical, periventricular, infratentorial, or spinal cord. He
was given 5 days of high-dose glucocorticosteroids for presumed
MS ﬂair, and this was continued until his ﬁnal admission, where
they were tapered once the diagnosis of cryptococcosis was estab-
lished. Although corticosteroid use for primary IRIS prophylaxis
is not recommended [1], in retrospect, this might have prevented
an IRIS phenomenon, such that dose reduction of corticosteroids
in combination with the initiation of antifungal therapy resulted
in signs of increased ICP, with development of cerebral edema
and rapid progression to death.
Autopsy ﬁndings demonstrated substantial evidence of high
fungal burden in both the meninges and lungs, which doubt-
lessly contributed to his ultimate demise. However, based on
the rapidity of clinical deterioration and progression to brain
death, we postulate that this patient developed a natalizumab-
mediated IRIS-like phenomenon. This has not been described
in patients receiving natalizumab. We know that natalizumab
prevents CNS migration of peripheral T cells through the
blood-brain barrier (BBB), and we hypothesize that rapid lysis
of cryptococcal organisms in the CNS with subsequent presen-
tation of those antigens to the CNS endothelial and antigen-
presenting cells overwhelmed the inhibition of α4-integrin by
natalizumab, allowing migration of peripheral CD4 T cells
across the BBB. Consequently, because patients on natalizumab
have been shown to exhibit normal peripheral CD4 T-cell pop-
ulations, we believe that the patient experienced massive migra-
tion of activated T cells across the BBB, which led to signiﬁcant
inﬂammation and cerebral edema. In addition, the median time
to development of IRIS in patients with HIV/AIDS is 4 weeks
[11] and corresponds with the reconstitution of peripheral CD4
populations. In this patient, an IRIS-like clinical deterioration
occurred in days, rather than weeks, which may be explained
by the presence of normal peripheral CD4 T-cell populations
at the time of induction antifungal therapy and was supported
by the autopsy ﬁndings of severe cerebral edema.
CONCLUSIONS
To date, there is little clinical experience to guide treatment of
cryptococcal IRIS in patients on natalizumab, and this case
underscores the importance of understanding the risk of IRIS
in these patients. We believe that these patients represent a
unique population in that the CNS-limited immunosuppression
places them at increased risk for IRIS after CNS opportunistic
infections, and we recommend that clinicians maintain a low
threshold for initiating high-dose glucocorticosteroids for
those patients who experience clinical deterioration consistent
with cerebral edema and IRIS.
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